Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Carol Bentley"'
Autor:
Iva Trenevska, Amanda P Anderson, Carol Bentley, Tasneem Hassanali, Sarah Wiblin, Shaun Maguire, Francesco Pezzella, Alison H Banham, Demin Li
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0249967 (2021)
T-cell receptor mimic (TCRm) antibodies have expanded the repertoire of antigens targetable by monoclonal antibodies, to include peptides derived from intracellular proteins that are presented by major histocompatibility complex class I (MHC-I) molec
Externí odkaz:
https://doaj.org/article/9ac3c2ac2ee84090b0a591c24d8b6a6d
Autor:
Demin Li, Carol Bentley, Jenna Yates, Maryam Salimi, Jenny Greig, Sarah Wiblin, Tasneem Hassanali, Alison H Banham
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176642 (2017)
Therapeutic monoclonal antibodies targeting cell surface or secreted antigens are among the most effective classes of novel immunotherapies. However, the majority of human proteins and established cancer biomarkers are intracellular. Peptides derived
Externí odkaz:
https://doaj.org/article/31aed34546f24c8981f2b91c934d61df
Autor:
Andrew J Massey, Jenifer Borgognoni, Carol Bentley, Nicolas Foloppe, Andrea Fiumana, Lee Walmsley
Publikováno v:
PLoS ONE, Vol 5, Iss 10, p e13123 (2010)
Checkpoint kinase 1 and 2 (Chk1/Chk2), and the Aurora kinases play a critical role in the activation of the DNA damage response and mitotic spindle checkpoints. We have identified a novel inhibitor of these kinases and utilized this molecule to probe
Externí odkaz:
https://doaj.org/article/903dfe8154ea49fc90bc02d89bad8167
Supplementary Figures 1-8 from Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy
Autor:
Alison H. Banham, Adrian L. Harris, Penny A. Handford, Nicola R. Sibson, James Larkin, Manuel Sarmiento-Soto, Sébastien Serres, Devon Sheppard, Chandramouli Chillakuri, Ji-Liang Li, Ellen Bealing, Jenna Yates, Stephen Stribbling, Sarah Watts, Tasneem Hassanali, Jenny Greig, Carol Bentley, Pat Whiteman, Demin Li, Massimo Masiero
1: JAG1 antibody characterization. 2: antibody inhibition of JAG1 mediated Notch signalling in tumor cell lines. 3: antibody inhibition of JAG1 signalling in vascular cells. 4: antibody inhibition of JAG1 signalling in HUVEC-HUVSMC co-culture. 5: eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d318461372ffb99d014884e8a0f6cac2
https://doi.org/10.1158/1535-7163.22510647
https://doi.org/10.1158/1535-7163.22510647
Autor:
Alison H. Banham, Adrian L. Harris, Penny A. Handford, Nicola R. Sibson, James Larkin, Manuel Sarmiento-Soto, Sébastien Serres, Devon Sheppard, Chandramouli Chillakuri, Ji-Liang Li, Ellen Bealing, Jenna Yates, Stephen Stribbling, Sarah Watts, Tasneem Hassanali, Jenny Greig, Carol Bentley, Pat Whiteman, Demin Li, Massimo Masiero
Supplementary material and methods. Supplementary table 1: cell lines and growth conditions. Supplementary table 2: Notch ligands and control protein for plate coating. Supplementary table 3: qPCR primers. Supplementary table 4: flow cytometry antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7722864810fcbbbc5d915df61ec1c5
https://doi.org/10.1158/1535-7163.22510644
https://doi.org/10.1158/1535-7163.22510644
Autor:
Alison H. Banham, Adrian L. Harris, Penny A. Handford, Nicola R. Sibson, James Larkin, Manuel Sarmiento-Soto, Sébastien Serres, Devon Sheppard, Chandramouli Chillakuri, Ji-Liang Li, Ellen Bealing, Jenna Yates, Stephen Stribbling, Sarah Watts, Tasneem Hassanali, Jenny Greig, Carol Bentley, Pat Whiteman, Demin Li, Massimo Masiero
The role of Notch signaling and its ligand JAGGED1 (JAG1) in tumor biology has been firmly established, making them appealing therapeutic targets for cancer treatment. Here, we report the development and characterization of human/rat-specific JAG1-ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4eef16695f97e97c7b4771d67bccc53
https://doi.org/10.1158/1535-7163.c.6539670
https://doi.org/10.1158/1535-7163.c.6539670
Autor:
Alison H. Banham, Mark S. Cragg, Bart Cornelissen, Benedikt M. Kessler, Nicola Ternette, Iva Trenevska, Marloes Olde Nordkamp, Jenny Greig, Jenna Yates, Tasneem Hassanali, Sofia Koustoulidou, Kirstie L.S. Cleary, Sarah Wiblin, Amanda Anderson, Carol Bentley, Demin Li
The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Because of its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ad45d5e1ad71de4423b965173872613
https://doi.org/10.1158/0008-5472.c.6508499.v1
https://doi.org/10.1158/0008-5472.c.6508499.v1
Autor:
Alison H. Banham, Mark S. Cragg, Bart Cornelissen, Benedikt M. Kessler, Nicola Ternette, Iva Trenevska, Marloes Olde Nordkamp, Jenny Greig, Jenna Yates, Tasneem Hassanali, Sofia Koustoulidou, Kirstie L.S. Cleary, Sarah Wiblin, Amanda Anderson, Carol Bentley, Demin Li
Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146962e10f0ef1461cb29601c26a6b8a
https://doi.org/10.1158/0008-5472.22412708.v1
https://doi.org/10.1158/0008-5472.22412708.v1
Autor:
Alison H. Banham, Mark S. Cragg, Bart Cornelissen, Benedikt M. Kessler, Nicola Ternette, Iva Trenevska, Marloes Olde Nordkamp, Jenny Greig, Jenna Yates, Tasneem Hassanali, Sofia Koustoulidou, Kirstie L.S. Cleary, Sarah Wiblin, Amanda Anderson, Carol Bentley, Demin Li
Suppl Table 1: Quantitation of T1-116C binding sites per target cell; Suppl Figure 1: Validation of the HLA-A2/p53RMP tetramer; Suppl Figure 2: ELISA screening of HLA-A2/p53RMP tetramer-reactive TCRm hybridoma supernatants; Suppl Figure 3: T1-116C st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c14b26228e504b028a1549db709d9c
https://doi.org/10.1158/0008-5472.22412711.v1
https://doi.org/10.1158/0008-5472.22412711.v1
Autor:
Ji-Liang Li, Demin Li, Stephen M. Stribbling, Penny A. Handford, Carol Bentley, Adrian L. Harris, Massimo Masiero, Sarah K. Watts, Susan M. Lea, Jenny Greig, Tasneem Hassanali, Pat Whiteman, Alison H. Banham, Jenna Yates
Publikováno v:
Molecular Cancer Therapeutics. 14:C128-C128
Background: The Notch pathway is an evolutionarily conserved cell-signaling system that plays an important role in both physiologic and pathologic conditions such as embryonic development and cancer. In the latter, Notch signaling has been reported t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aef8a2ec8c46bba5b9d1cccbb0f04bd2
https://doi.org/10.1158/1535-7163.targ-15-c128
https://doi.org/10.1158/1535-7163.targ-15-c128